Pattern of asthma medication use among children from a large urban center in Brazil. by Santos, Djanilson Barbosa et al.
Santos, DB; Cruz, AA; de Magalhes Simes, S; Rodrigues, LC; Ca-
margos, PA; Coelho, HL; Barreto, ML (2012) Pattern of asthma
medication use among children from a large urban center in Brazil.
European journal of clinical pharmacology, 68 (1). pp. 73-82. ISSN
0031-6970
Downloaded from: http://researchonline.lshtm.ac.uk/56069/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
PHARMACOEPIDEMIOLOGY AND PRESCRIPTION
Pattern of asthma medication use among children
from a large urban center in Brazil
Djanilson Barbosa Santos & Alvaro A. Cruz & Silvia de Magalhães Simões &
Laura C. Rodrigues & Paulo Augusto Moreira Camargos &
Helena Lutescia Luna Coelho & Mauricio L. Barreto
Received: 10 May 2011 /Accepted: 14 June 2011 /Published online: 30 June 2011
# Springer-Verlag 2011
Abstract
Purpose Despite the advances in asthma therapeutics, there
are few data on the use and determinants of anti-asthmatic
drugs in the general population of children. This study
describes the use of asthma medications among children in
the general population and in children with current asthma,
living in a large urban center in Brazil.
Methods A population-based cross-sectional survey, aimed
at analyzing asthma determinants, was conducted with
1,382 children aged 4–11 years, between February and May
2006, in Salvador, Brazil. At baseline, an extensive
questionnaire was applied, including questions about the
use of asthma medications in the last 12 months.
Results In all studied children (n=1,382) aged 4–11 years,
oral beta2-agonists were the drugs most frequently used
(9.8%), followed by short-acting inhaled beta2-agonists
(4.3%) and systemic corticosteroids (1.6%). Anti-
asthmatic drug use was higher among males than females,
and it significantly decreased with age in both genders. A
total of 312 children (22.6%) reported current asthma, and
62% of them were not being treated with any anti-
asthmatic drugs. Of all those who reported following a
certain type of treatment, 20% used oral beta2-agonists
alone; 6.1%, short-acting inhaled beta2-agonists alone;
and 4.8%, a combination of both drugs. Anti-asthmatic
drug use did not differ according to socioeconomic status,
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except for the use of inhaled beta2-agonists and systemic
corticosteroids.
Conclusions An overwhelming majority of asthmatic
children were not using long-term medications for
asthma, in particular inhaled corticosteroids, regardless
of the severity of their disease. This result points to the
deficiencies of the Brazilian public health system in
recognizing this important pharmacological need for
child care and thereby limiting the access of these
children to a group of efficacious, available, and low
risk therapeutic medications.
Keywords Asthma . Pharmacoepidemiology . Asthma .
Therapy . Children . Prevalence . Cross-sectional studies .
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Introduction
Asthma is a chronic disease, very frequent in children and
adolescents, and its prevalence has increased in recent decades,
although with significant differences among countries [1, 2].
Despite therapeutic advances achieved in the last decades,
asthma continues to be an important public health problem, and
it requires a substantial use of health services [1–3]. Among the
factors influencing the elevated morbidity of asthma, the
following stand out: genetic predisposition, environmental
factors, lifestyle, under-diagnosis, and ineffective treatment,
including inadequate management of the disease and the
adoption of outdated therapeutic practices [4, 5].
Current international and national guidelines, directives,
and consensus recognize that asthma is an inflammatory
disease and that inhaled corticosteroids are the most effective
therapy available, as they have a prolonged action and have
been available for over 30 years. However, recent studies in
different populations have shown the under-use of this class of
drugs and the great use of other classes of drugs, the short-
acting β-agonists [6–8]. Therapy based on the preferred use
of these β-agonists results in inadequate control of asthma
and may be contributing to a greater number of asthma-
related deaths [9]. In the United States, there is evidence that
morbidity and mortality from asthma have increased in
children who live in unfavorable socioeconomic conditions
[10]. One of the probable explanations is that asthma, when
treated only during exacerbations with drugs that are
effective, yet short-acting, increases the frequency of visits
to emergency rooms and the risk of death [11, 12].
Prevalence of asthma in children in Latin America, especial-
ly in Brazil, is high [2, 6, 13].
Standard population surveys have been used as the main
instrument to estimate the prevalence of asthma in the
population [14]. In children aged 6–7 years and 13–
14 years, living in five Brazilian regions, prevalence of
wheezing in the last 12 months ranged from 24.3 to 19.0%
[15]. Rosário Filho reported an increase in spending on
drugs for asthma treatment and in hospitalizations due to
this disease [16]. Other studies performed in children with
asthma in the public health care facilities in Brazil revealed
small proportions of use of anti-inflammatory treatment,
ranging from 6.0 to 14.0% [17, 18]. In Brazil, the lack of
population-based studies on the use of anti-asthmatics in
children, as well as on the reasons for this lack, necessitates
such studies, particularly as the use of these drugs is
considered an indirect indicator of quality of care provided
to asthmatic children. Thus, the objectives of this study
were (1) to determine the pattern of consumption of anti-
asthmatic drugs and (2) to analyze factors associated with
the patterns found, in children living in poorer areas of an
urban center of northeastern Brazil.
Methods
Study design and population
A population-based cross-sectional study was performed in
a cohort of children in the urban area of the city of Salvador
(northeastern Brazil) between February and May 2006. The
methods of the longitudinal study are described in detail
elsewhere [19]. In brief, the sample was selected randomly
from 24 areas, representative of the population living in
areas of Salvador that had no sanitation at the time of the
cohort recruitment. The original sample had 1,445 children.
This is a cross-sectional study of these children, and 1,382
had complete data to participate in this specific analysis.
Data collection
A structured pre-coded questionnaire was used. It included
a specific component on the use of medications for
respiratory diseases, and another, involving demographic
and socioeconomic variables, health conditions and ques-
tions about asthma-related symptoms based on the Brazilian
Portuguese version of the International Study of Allergies
and Asthma in Children (ISAAC) Questionnaire [14].
Table 1 gives further details of the questions used in this
study. This instrument was submitted to a pre-pilot
evaluation to test the comprehensibility of the questions.
After the necessary corrections were made, a pilot study
was performed with 10% of the source population for the
final test of the questionnaire, development of the manual
of instructions, and training of interviewers. Questionnaires
were applied using home interviews, conducted with the
mothers or adults responsible for the children. In case of
absence of interviewees or refusal, interviewers would
return to these homes at least two more times.
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Asthma definition
Asthma was defined as the occurrence of wheezing in the
12 months preceding the application of the questionnaire,
associated with at least one of the following criteria:
diagnosis of asthma some time in life, at least four episodes
of wheezing in the chest in the last year, history of
wheezing in the chest during or after physical exercises,
or having woken up at least one night per week due to
wheezing in the last 12 months. Children who met these
criteria and had taken ß-agonists daily or reported their use
during hospitalizations due to acute asthma in the last
12 months comprised the group classified with the
diagnosis of severe asthma.
Asthma medication use
The use of asthma medication in the 12 months preceding
the interview was measured by answering the following
question: “In the last 12 months, did your child use any
medication (pills, syrups, nebulizers, or pressurized metered
dose inhalers) for wheezing, whistling, or asthma?” Based
on the responses to these questions, the medicines for
asthma taken by children and reported by mothers were
classified as follows: (1) quick-relief medications to treat
acute symptoms and exacerbations (short-acting ß-agonists,
ipratropium bromide, and systemic corticosteroids) and (2)
long-term control medications or “controllers” (inhaled
corticosteroids, prolonged-release theophylline, long-acting
ß-agonists, systemic corticosteroids, and antileukotrienes).
Covariables
A total of five sets of variables were considered: demo-
graphic, socioeconomic, health conditions, life habits, and
severity of asthma. The following were considered as
socioeconomic and demographic variables: child’s age and
sex; mother’s age, ethnicity (white or black), and level of
Table 1 Questions on asthma medication use and other factors together with the answer alternatives presented to children from a large urban
center in Brazil
Administered questions Answer alternatives
Health conditions
In general, how has the health of your child been in the last 15 days? Excellent, very good, good, poor, very poor
Exposure to cigarette smoke
Does your child’s mother smoke cigarettes? No, yes
Are there other people living in the house who smoke cigarettes, including parents? No, yes
Questions on wheezing and asthma
Has your child ever had wheezing or whistling in the chest at any time in the past? No, yes
Has your child had wheezing or whistling in the chest in the last 12 months? No, yes
How many attacks of wheezing has your child had in the last 12 months? None, 1–3, 4–12, more than 12
In the last 12 months, how often, on average, has your child’s sleep been disturbed due
to wheezing?
Never woken with wheezing, less than one night per
week, one or more nights per week
In the last 12 months, has wheezing ever been severe enough to limit your child’s
speech to only one or two words at a time between breaths?
No, yes
Has your child ever had asthma? No, yes
In the last 12 months, has your child’s chest sounded wheezy during or after exercise? No, yes
In the last 12 months, has your child had a dry cough at night, apart from a cough
associated with a cold or chest infection?
No, yes
Asthma management
In the last 12 months, has your child used any medicines, pills, puffers, or other
medication for wheezing or asthma?
No, yes
Medicines If you answered “yes,” please name the medication(s)
How often? When wheezy; regularly (i.e., every day for at least
2 months of the year)
In the past 12 months, how many visits has your child made to any of the following
health professionals for wheezing or asthma?
Doctor None, 1–3, 4–12, >12
Hospital emergency department None, 1–3, 4–12, >12
In the past 12 months, how many times has your child been admitted to hospital
because of wheezing or asthma?
None, 1, 2, >2
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education; and monthly household income (<1, 1–2, 3–5×
minimum wage). The national minimum wage at the time
of the survey corresponded to US$100. Child health
conditions (excellent/very good, good, poor/very poor)
were established by the mother’s self-perception of health.
Exposure to cigarette smoke was defined by current
maternal smoking (yes/no) and presence of other smokers
in the household (yes/no). Information about the severity of
asthma in the last 12 months consisted of the number of
episodes of wheezing (none, 1–3, and ≥4); frequency of
awakenings at night due to wheezing (has never woken up
with wheezing, less than one night per week, one or more
nights per week); difficulty in pronouncing two consecutive
words during exacerbations (yes/no); perception of wheez-
ing during or after exercising (yes/no); visits to the doctor
while having exacerbations (none, 1–3, ≥4 times); visits to
emergency services due to exacerbations (none, one or
more times) and hospitalizations due to asthma (none, one
or more times).
Data analysis
Prevalence of asthma medication use according to sex and
age group was calculated by the proportion of children who
had taken at least one of these medicines in the last
12 months, divided by the total number of children in each
age group per sex. In the bivariate analysis, chi-squared test
was used to compare proportions (Mantel-Haenszel) and
the linear trend test for ordinal variables. In the present
study, analysis was performed by comparing children who
had used asthma medication with those who had taken
other types of medicines or not, according to maternal
information. A P value <0.05 was considered significant.
Data analysis was performed using Stata software, version
9.0 (StataCorp, College Station, TX).
Ethical approval
Approval was obtained from the Brazilian Research Ethics
Committee. Written informed consent was obtained from
the legal guardian of each child studied.
Results
The 1,382 children studied represent 95.6% of the cohort
(1,445 individuals). Of all children, 63 were excluded
from this analysis: 26 because they were not found as a
result of change of address and 37 because complete
information, provided by the mothers and obtained in
previous survey, was not available. Of the 1,382 studied
children, 12.3% had taken asthma medication specifically
(R03) and 219 children (15.8%) had taken medicines for
respiratory problems in the last 12 months, as reported
by their mothers. The use of medication for asthma was
similar between boys and girls, at 13 and 12%,
respectively. The prevalence of use of medicines de-
creased significantly with age (P<0.001) in both sexes; in
the extremes of age groups into which the study population
was categorized, 4–5 and 9–11 years, the prevalence
decreased from 17.2 to 8.0% in females (P=0.005) and from
20.3 to 8.8% in males (P=0.001) (Table 2).
Oral ß-agonists as monotherapy were the therapeutic
regimen most frequently reported by mothers, with inhaled
ß-agonists following far behind (Fig. 1). The oral ß-agonists
most frequently used in syrup formulation were salbutamol
(87.2%) and fenoterol (9.5%), whose consumption was
reported by 138 children, of which 88 (64%) used them
intermittently. Inhaled ß-agonists were consumed by 59
children, of which 21 (36%) did so on a daily basis. In
contrast to the oral ß-agonists, the inhaled ß-agonist most
frequently used was nebulized fenoterol (93.1%). Systemic
corticosteroids, especially prednisone and prednisolone,
were used by 22 (1.6%) children, of which 14 (64%) used
these intermittently (data not show).
Of the 312 children with asthma, 37.2% had taken
medications for asthma (R03) in the last 12 months.
Medications for asthma were equally used by girls and
boys, at 38 and 36%, respectively (Table 2). The frequency
of medication did not increase with age (P=0.886). A
perception of the child’s health reported by the mother as
being poorest was associated with greater consumption of
medication (P<0.001). With regard to the severity of
asthma in the last 12 months, consumption of medication
was greater in children with difficulty in pronouncing two
consecutive complete words during exacerbations (52%),
those wheezing during or after exercising (46%), and those
who experienced one or more hospitalizations due to
exacerbations of asthma in the last year (51%). Oral ß-
agonist as monotherapy was the therapeutic regimen most
frequently reported (19.9%), followed by inhaled ß-agonists
(6.1%), with 15 (4.8%) children receiving both (Fig. 1).
Oral ß-agonists (salbutamol and fenoterol were the most
frequently used) were used by 91 children and, of these, 59
(64.8%) consumed them intermittently. A total of 40
children reported the use of inhaled ß-agonists, especially
salbutamol and fenoterol, of which 16 (40.0%) used daily.
Systemic corticosteroids (especially prednisone and pred-
nisolone) were used by 17 (5.4%) children, of which 70.1%
reported occasional use (data not show).
As shown in Table 3, the use of medication for asthma in
children did not differ significantly according to monthly
household income, except for the use of inhaled β-agonists
and systemic corticosteroids, whose use was more frequent
in children from families with a monthly income above the
minimum wage. The use of oral β-agonists was signifi-
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cantly more frequent in children who met certain character-
istics related to the severity of asthma in the last 12 months.
In Table 4, characteristics of children who were categorized
as having severe asthma (n=110; 35.3%) compared with
those with nonsevere asthma (n=202; 64.7%) are pre-
sented. Social and demographic differences were not
observed between the two groups, but as expected the
severe cases present a great frequency of severe symptoms
and more frequent use of systemic corticosteroids.
Discussion
In this population-based study conducted among children
living in poor neighborhoods from a large urban center in
Brazil, a significant underuse of long-term control medi-
cations was found among those reported with asthma. In
addition, 62.8% of the 312 children classified as asthmatic
reported no use of any specific medication. Studies show
that underuse of medication by certain children results
mainly from their families’ low socioeconomic level, thus
hindering drug acquisition; characteristics of the health
system; and professional practices [7, 20].
In Brazil, asthma is responsible for around 350,000 hospital-
izations annually and represents the fourth cause of hospital-
izations (2.3% of the total) in the SUS (Unified Health System)
and the third cause of hospitalizations among children and
Table 2 The number and percentage of children using asthma
medication in a population-based sample from an urban center in
Brazil in relation to social, environmental, demographic, and health
characteristics
Characteristics Children with
asthma (n=312)
Total sample of
children (n=1,382)
Total using any medication
for asthma
116 (37) 170 (12)
Demographics
Age (years)
4–5 36 (37) 50 (19)*
6 27 (38) 41 (13)
7–8 31 (35) 50 (11)
9–11 22 (42) 29 (8)
Sex
Male 62 (36) 94 (13)
Female 54 (38) 76 (12)
Socioeconomic
Maternal ethnicity
White 12 (44) 19 (14)
Black 104 (36) 151 (12)
Monthly household income (minimum wages)
<1× MW 65 (37) 95 (13)
1–2× MW 33 (38) 46 (11)
3–5× MW 18 (37) 29 (12)
Maternal level of education (years)
0–4 29 (36) 39 (13)
5–8 37 (40) 53 (12)
9 or more 49 (36) 76 (12)
Maternal age (years)
10–29 50 (37) 84 (15)*
30–39 48 (37) 61 (11)
40–80 18 (38) 25 (10)
Health conditions
Perception of health of the child reported by mother
Excellent 8 (35)* 15 (7)**
Good 65 (31) 102 (11)
Poor 43 (53) 53 (26)
Exposure to cigarette smoke
Current maternal smoking
No 101 (38) 153 (13)
Yes 14 (33) 16 (9)
Presence of other smokers in the household
No 85 (36) 131 (12)
Yes 31 (40) 39 (13)
Severity of asthma in the last 12 months
Number of exacerbations of wheezing
None 3 (18) 4 (1)**
1–3 75 (34) 91 (31)
≥4 38 (53) 38 (53)
Awakenings at night due to wheezing
Never woke up 12 (40) 29 (3)
Table 2 (continued)
Characteristics Children with
asthma (n=312)
Total sample of
children (n=1,382)
Less than one night per week 52 (31) 52 (31)
One or more nights per week 52 (45) 52 (45)
Difficulties in pronouncing two consecutive words during
exacerbations
No 72 (32)** 88 (7)**
Yes 44 (52) 45 (51)
Wheezing during or after exercising
No 64 (32)* 117 (9)**
Yes 52 (46) 53 (39)
Visits to the doctor
None 44 (34) 73 (7)**
1–3 52 (37) 62 (26)
≥4 19 (44) 20 (41)
Visits to emergency services
None 105 (36) 145 (11)*
One or more 11 (52) 11 (33)
Hospitalizations
None 74 (32)* 114 (9)**
One or more 42 (51) 42 (42)
*P <0.05; **P <0.001
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young adults. In 1996, SUS spent US$43 million on hospital-
izations due to asthma, 2.8% of the total annual spending and
the third highest value spent on a specific disease [21–23].
Only 37% of asthmatic children had used medication for
asthma in the 12 months prior to the survey. The most
frequently used medicines by pharmacological group were,
in decreasing order: oral ß-agonists, inhaled ß-agonists, and
systemic corticosteroids. The distribution by age showed a
more frequent use of inhaled β-agonists by older children
and of systemic corticosteroids by younger ones. This is
probably a result of the difficulties in teaching younger
children how to use an inhaler, according to similar findings
among German asthmatic children [24]. Of the asthmatic
children, 12.7% had used systemic corticosteroids alone or
in association with other anti-asthmatic medications. How-
ever, this group of drugs is not recommended for asthma
treatment, due to an increased risk of bone fractures in
children even when used for short periods of time [25, 26].
A 
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Fig. 1a, b Use of medications for asthma in monotherapy or in combination, in the last 12 months, among children in Salvador, Brazil. a Quick-relief
medications for exacerbations, b controller medication
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In this studied population, it has already been shown that
the use of medicine, in general, is irrational for some
pharmacological groups, in particular antibiotics and
analgesics/antipyretics [27]. In the present study we showed
that the patterns of use of medications for asthma are in
great divergence with the recommendations established in
guidelines that emphasize the need to use daily preventive
anti-inflammatory drugs in children with asthma, be it mild,
moderate, or severe [28]. Inhaled corticosteroids, the main
pharmacological choice for control of this disease, were
reported to have been used by only one child in this
population. Other studies conducted in Brazil, although
Table 3 Type of asthma medication used by children with reported wheezing in a population-based sample from an urban center in Brazil
Numbers Oral ß-agonists (%) Inhaled ß-agonists (%) Systemic corticosteroids (%) No medicine (%)
Overall 312
Sex
Male 171 27.5 11.7 7.0 57.3
Female 141 31.2 14.2 3.5 56.7
Age (years)
4–5 98 26.5 14.3 8.2 55.1
6 72 33.3 12.5 2.8 55.6
7–8 89 28.1 10.1 4.5 62.9
9–11 53 30.2 15.1 5.7 52.8
Maternal ethnicity
White 27 33.3 22.2 7.4 51.8
Black 285 28.8 11.9 5.3 42.1
Monthly household income (minimum wages)
<1× MW 175 30.9 8.6* 2.3* 41.1
1–5× MW 137 27.0 18.3 9.5 45.3
Indicators of severity of asthma in the last 12 months
Number of exacerbations of wheezing
None 17 17.7* 5.9 0.0 82.4*
1–3 223 25.1 13.5 4.5 59.2
≥4 72 44.4 12.5 9.7 44.4
Awakenings at night due to wheezing
Never woke up 30 30.0 16.7 3.3 56.7
Less than one night per week 167 24.6 9.6 4.8 62.3
One or more nights per week 115 35.7 16.5 7.0 49.6
Difficulty in pronouncing two consecutive words during exacerbations
No 227 23.8* 11.9 4.4 61.2*
Yes 85 43.5 15.3 8.2 45.9
Wheezing during or after exercising
No 198 23.7* 12.1 2.5* 60.6
Yes 114 38.6 14.0 10.5 50.9
Visits to the doctor
None 129 29.5 8.5* 4.7 58.9
1–3 139 28.1 13.7 6.5 56.8
≥4 43 30.2 23.3 4.7 53.5
Visits to emergency services
None 291 28.2 12.7 5.2 57.7
One or more 21 42.9 14.3 9.5 47.6
Hospitalizations
None 229 24.9* 11.4 2.2* 60.7*
One or more 83 41.0 16.9 14.5 47.0
*P <0.05
Eur J Clin Pharmacol (2012) 68:73–82 79
focused on children cared for in health units, found frequencies
of use of inhaled corticosteroids between 2 and 6% [18, 29].
The reasons for underuse of inhaled corticosteroids in
our context and the fact that well established recommenda-
tions are not followed reflect flaws in public health policies
aimed at asthma, including the complete absence of
strategies to increase prescribers’ adherence to the asthma
program recommendations, drug availability and afford-
ability flaws, and lack of continuing education for families
[6, 17]. Inhaled corticosteroids are listed by the World
Health Organization as essential medications, but they cost
more than what low-income families can afford, thus
emphasizing the need for these to be available in SUS
primary health care units through the establishment of a
broad public program for asthma control [29].
There were no significant associations between overall use
of asthma medication and monthly household income, a result
that is similar to those observed in other studies [24, 30].
However, inhaled β-agonists and systemic corticosteroids
were used more frequently in children whose monthly
household income was higher than the minimum wage. A
similar finding was observed in a study among asthmatic
German children where the use of systemic corticosteroids
was more frequent in the richest ones [24]. In a study
performed with a group of low-income asthmatic children in
NewYork City, it was observed that many families understood
asthma as an episodic disease, thus giving priority to
symptomatic rather than preventive therapies [31, 32].
Inadequate treatment of asthma leads to the frequent use
of emergency services and hospitalizations due to exacer-
bations and leads to a higher risk of complications [33, 34].
For the low-income population in Brazil, the emergency
room is often the access to health services. In the case of
asthma, children visit the emergency room motivated by
exacerbations of a disease that is not controlled properly
[29]. The present study demonstrated this situation. None of
the 21 asthmatic children who frequently visited the
emergency rooms used long-term control medications for
asthma (inhaled corticosteroids, antileukotrienes, or
prolonged-release theophylline). Constant visits to emer-
gency units, motivated by exacerbations of asthma, are the
best indicator of inadequate treatment [33].
The low quality of care provided to children with asthma
was best evidenced in this study by the fact that half of the
children classified as having severe asthma had not used
any class of medication against asthma in the last
12 months. Moreover, of the 312 children who had asthma,
83 (28%) had had at least one episode of hospitalization in
the last 12 months, and 51% were treated only with quick-
relief medication (41% oral β-agonist and 16.9% inhaled
β-agonist). In population-based studies, the rates of
hospitalizations for asthmatic patients represent the joint
effect of the prevalence and severity of the disease and the
quality of health care provided. Studies have shown that
intervention with inhaled corticosteroids contributes to
decreased morbidity and mortality [35, 36] and hospital-
izations [21] due to asthma.
Childhood asthma was highly prevalent in the studied
population in this low-income urban community setting in
Brazil [13], but an overwhelming majority of asthmatic
children did not use long-term medications for asthma, in
particular inhaled corticosteroids, regardless of the severity
of their disease. Brazil has a comprehensive health system
[37], but this result points to deficiencies in recognizing this
important pharmacological need for child care, and thereby
the access of these children to a group of efficacious and
Characteristics Number Severe asthma
(n=110) (%)
Nonsevere asthma
(n=202) (%)
P-value
Black mother 285 88.2 93.1 0.142
Male 171 59.1 52.5 0.262
7–8 years of age 89 35.5 24.8 0.174
Household income less than minimum wage 175 57.3 55.4 0.756
Severity of asthma in the last 12 months
1–3 exacerbations of wheezing 223 65.5 74.8 0.012
Less than one awakening at night
per week due to wheezing
167 53.6 53.5 0.313
Difficulty in pronouncing two consecutive
words during exacerbations
85 44.6 17.8 <0.001
Wheezing during or after exercising 114 49.1 29.7 0.001
One or more visits to the doctor 182 68.8 53.0 0.007
Visits to the emergency room 21 10.9 4.5 0.030
Use of corticosteroids in the last 12 months
Systemic 17 12.7 1.5 <0.001
Inhaled 1 0.9 0
Table 4 Characteristics of
children classified as having
severe asthma compared with
children with nonsevere asthma
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low risk therapeutic medications is limited. The lack of
access to proper treatment with inhaled corticosteroids has
put children at risk through their use of systemic cortico-
steroids. They may have been well prescribed to treat
exacerbations that could have been avoided with the use of
inhaled corticosteroids, which have an insignificant rate of
systemic side effects. But, for an asthma control program to
be effective—in addition to ensuring the availability of
adequate pharmacological treatments—the program must
be integrated with public education aimed at asthma
patients and all health professionals, rather than prescribers
only.
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